Tezepelumab treatment was well tolerated for up to 2 years and resulted in sustained,
clinically meaningful reductions in asthma exacerbations in individuals with severe,
uncontrolled asthma. These findings are consistent with previous randomised, placebo-controlled
studies and show the long-term safety and sustained efficacy of tezepelumab in individuals
with severe, uncontrolled asthma.